2024-517091-38-00招募中1 期
A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 55
- 试验地点
- 24
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (24)
Loading locations...
相似试验
招募中
1 期
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer2023-510307-22-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.116
已完成
1 期
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer2022-502125-17-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.14
招募中
1 期
A study to test different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.2024-513100-34-00Boehringer Ingelheim International GmbH129
招募中
1 期
A study to test whether multiple doses of BI 456906 have an effect on cardiac safety in people with overweight or obesity.2023-506375-10-00Boehringer Ingelheim International GmbH110
招募中
1 期
A study to test how well multiple doses of BI 3810477 are tolerated by healthy adults.2024-519327-20-00Boehringer Ingelheim International GmbH48